PROs Support Practice-Changing RUBY Trial in Endometrial Cancer
Adding dostarlimab upfront does not add significant toxicity for patients, says Pamela Soliman
Source: medpagetoday.com
Stay updated with breaking news from Pamelat Soliman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding dostarlimab upfront does not add significant toxicity for patients, says Pamela Soliman
Pamela T. Soliman, MD, MPH, discusses the use of circulating tumor DNA a clinical trial end point in endometrial cancer.
Complex surgery is much more likely for advanced ovarian cancer in women with mesenchymal tumors and complex preoperative CT findings.